ADP receptor antagonism: what's in the pipeline?

@article{Angiolillo2007ADPRA,
  title={ADP receptor antagonism: what's in the pipeline?},
  author={Dominick Joseph Angiolillo},
  journal={American journal of cardiovascular drugs : drugs, devices, and other interventions},
  year={2007},
  volume={7 6},
  pages={
          423-32
        }
}
ADP is one of the most important mediators of both physiologic hemostasis and thrombosis. Development and utilization of agents that block ADP receptors on the platelet membrane, namely thienopyridines, has represented a major advancement for treatment of patients undergoing percutaneous coronary interventions and those with acute coronary syndromes. Currently, clopidogrel, a second-generation thienopyridine that inhibits the ADP P2Y(12) receptor, represents the treatment of choice, in addition… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Similar Papers

Loading similar papers…